Clinical trial
A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Combination With Indication-specific Chemotherapy or Chemoradiotherapy in Participants Across Multiple Indications in India (KEYNOTE-G44)
NCT07801027 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Combination With Indication-specific Chemotherapy or Chemoradiotherapy in Participants Across Multiple Indications in India (KEYNOTE-G44)
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- November 6, 2026
- Completion date
- January 31, 2030
- Enrollment
- 150 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
biliary tract carcinoma, gastric neoplasms, gastroesophageal junction adenocarcinoma, neoplasm malignant, uterine cervical neoplasms